Embla Medical hf (OSSR) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

DKK 15,480 Million ()

P/E

26.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.42

Return on Equity

9.41%

Price to Book

2.81

Revenue and Profits:

Net Sales:

1,529 Million

(Quarterly Results - Jun 2025)

Net Profit:

139 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

15.17%

6 Months

10.71%

1 Year

1.92%

2 Years

31.45%

3 Years

13.94%

4 Years

-7.0%

5 Years

-20.68%

Embla Medical hf for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

7.28%

EBIT Growth (5y)

15.00%

EBIT to Interest (avg)

5.28

Debt to EBITDA (avg)

2.04

Net Debt to Equity (avg)

0.39

Sales to Capital Employed (avg)

0.72

Tax Ratio

24.52%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

8.84%

ROE (avg)

7.25%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.52

EV to EBIT

18.84

EV to EBITDA

12.69

EV to Capital Employed

2.09

EV to Sales

2.57

PEG Ratio

1.39

Dividend Yield

ROCE (Latest)

11.11%

ROE (Latest)

9.52%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 1.80% vs 8.96% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -0.07% vs 27.99% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,528.80",
          "val2": "1,501.80",
          "chgp": "1.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "317.20",
          "val2": "325.10",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "33.30",
          "val2": "44.60",
          "chgp": "-25.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "138.90",
          "val2": "139.00",
          "chgp": "-0.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "143.20%",
          "val2": "152.70%",
          "chgp": "-0.95%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 8.86% vs 6.45% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.32% vs 32.49% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,894.90",
          "val2": "5,414.90",
          "chgp": "8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,163.40",
          "val2": "946.80",
          "chgp": "22.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "170.60",
          "val2": "142.80",
          "chgp": "19.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "475.50",
          "val2": "405.30",
          "chgp": "17.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "131.90%",
          "val2": "111.30%",
          "chgp": "2.06%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

1,528.80

1,501.80

1.80%

Operating Profit (PBDIT) excl Other Income

317.20

325.10

-2.43%

Interest

33.30

44.60

-25.34%

Exceptional Items

0.00

Consolidate Net Profit

138.90

139.00

-0.07%

Operating Profit Margin (Excl OI)

143.20%

152.70%

-0.95%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 1.80% vs 8.96% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -0.07% vs 27.99% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5,894.90

5,414.90

8.86%

Operating Profit (PBDIT) excl Other Income

1,163.40

946.80

22.88%

Interest

170.60

142.80

19.47%

Exceptional Items

0.00

Consolidate Net Profit

475.50

405.30

17.32%

Operating Profit Margin (Excl OI)

131.90%

111.30%

2.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 8.86% vs 6.45% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 17.32% vs 32.49% in Dec 2023

All Annual Results

Company CV

About Embla Medical hf

Embla Medical hf

Pharmaceuticals & Biotechnology

Ossur hf is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. The Company is divided into three market segments: Bracing and Supports, which offers products for therapeutic and preventive purposes; Prosthetics, which offers products for amputees, which include sockets, sleeves, prosthetic knees and feet, as well as supporting components, and Compression Therapy, which offers treatment for venous ulcers and edema. The Company's main markets are North America, Europe and Asia. It has subsidiaries in Iceland, the United States, Canada, Mexico, France, the Netherlands, the United Kingdom, Sweden, Norway, Spain, South Africa, China and Australia.

Company Coordinates

Company Details

Grjothals 1-5 , REYKJAVIK None : 110

Tel: 354 5 151300354 515 1380

https://www.ossur.com/corporate/

Registrar Details